{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Exploratory outcome, results not included in this submission. EORTC QLQ-CR29 is designed to be administered in addition to EORTC QLQ-C30. The EORTC QLQ-CR29 is a specific questionnaire for Colorectal Cancer. Scale from 0 to 100, A higher scale represents better function and a higher quality of life.","groups":[{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"T-DXd 5.4 mg/kg Q3W"},{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).","id":"OG001","title":"T-DXd 6.4 mg/kg Q3W"}],"populationDescription":"Exploratory outcome, results not included in this submission","reportingStatus":"POSTED","timeFrame":"From baseline to data cut off, up to approximately 19 months","title":"Change From Baseline in Patient-Reported Outcomes (PROs) in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Colorectal Cancer 29 (QLQ-CR29)","type":"OTHER_PRE_SPECIFIED"}